TABLE 2

Genotype distribution of SNPs in the ELMO1

Position (major/minor)Major/majorMajor/minorMinor/minorTotal
Intron 16+101856 (A/G)
    Case group326 (51.9)252 (40.1)50 (8.0)628
    Control group242 (57.6)165 (39.3)13 (3.1)420
Intron 16+104353 (A/G)
    Case group296 (46.7)269 (42.4)69 (10.9)634
    Control group211 (49.6)195 (45.9)19 (4.5)425
Intron 16+105608 (C/T)
    Case group355 (56.2)237 (37.5)40 (6.3)632
    Control group263 (62.8)148 (35.3)8 (1.9)419
Intron 16+114454 (C/T)
    Case group229 (41.0)262 (47.0)67 (12.0)558
    Control group161 (44.0)184 (50.3)21 (5.7)366
Intron 17+5495 (A/G)
    Case group286 (45.1)278 (43.9)69 (10.9)633
    Control group212 (49.9)197 (46.3)16 (3.8)425
Intron 18+9170 (A/G)*
    Case group244 (37.7)304 (47.0)99 (15.3)647
    Control group178 (41.8)221 (51.9)27 (6.3)426
Intron 19+2430 (G/A)
    Case group239 (37.6)306 (48.1)91 (14.3)636
    Control group182 (42.9)215 (50.7)27 (6.4)424
Intron 20+1239 (A/G)
    Case group311 (48.7)265 (41.5)63 (9.9)639
    Control group214 (51.0)189 (45.0)17 (4.0)420
3′ flanking + 735 (A/T)
    Case group316 (50.1)257 (40.7)58 (9.2)631
    Control group221 (52.5)183 (43.5)17 (4.0)421
Intron 1+5853 (T/G)
    Case group310 (48.7)278 (43.7)48 (7.5)636
    Control group195 (46.2)174 (41.2)53 (12.6)422
  • Genotype data are presented as number of subjects (%). *Landmark SNP used for the genome-wide screening.